AQR discloses 5.05% Sarepta Therapeutics stake

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 5,329,691 shares of Sarepta Therapeutics, Inc. common stock, equal to 5.05% of the class as of June 30, 2026.

Rhea-AI Filing Summary

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 5,329,691 shares of Sarepta Therapeutics, Inc. common stock, equal to 5.05% of the class as of June 30, 2026. The reported amount includes Convertible Notes representing 1,004,002 shares of common stock.

Both entities report shared voting power over 4,916,753 shares and shared dispositive power over 5,329,691 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule 13G/A Amendment No. 1 is filed on behalf of both.

Key Figures

Beneficial ownership: 5,329,691 shares Ownership percentage: 5.05 % Convertible Notes component: 1,004,002 shares +2 more

5 metrics

Beneficial ownership 5,329,691 shares Total Sarepta common shares beneficially owned by AQR entities as of June 30, 2026

Ownership percentage 5.05 % Percent of Sarepta common stock class beneficially owned by AQR entities

Convertible Notes component 1,004,002 shares Shares of Sarepta common stock represented by Convertible Notes included in the reported amount

Shared voting power 4,916,753 shares Shares of Sarepta common stock over which AQR entities have shared voting power

Shared dispositive power 5,329,691 shares Shares of Sarepta common stock over which AQR entities have shared dispositive power

Key Terms

beneficially owned, Convertible Notes, shared voting power, shared dispositive power, +1 more

5 terms

beneficially owned financial

"Ownership (a) | Amount beneficially owned: 5,329,691"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Convertible Notes financial

"The reported amount includes Convertible Notes representing 1,004,002 shares"

Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.

shared voting power financial

"Shared Voting Power 4,916,753.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 5,329,691.00"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Sarepta Therapeutics (SRPT) does AQR report in this Schedule 13G/A?

AQR reports beneficial ownership of 5,329,691 shares of Sarepta Therapeutics common stock, representing 5.05% of the outstanding class as of June 30, 2026.

How much of AQR’s reported SRPT position comes from convertible notes?

The filing states that the reported amount includes Convertible Notes representing 1,004,002 shares of Sarepta Therapeutics common stock, which are counted within the 5,329,691 shares beneficially owned.

What voting power over Sarepta Therapeutics (SRPT) shares does AQR have?

AQR Capital Management, LLC and its parent report shared voting power over 4,916,753 shares of Sarepta common stock and no sole voting power over any shares in this position.

What dispositive power over SRPT shares is reported by AQR entities?

The AQR entities report shared dispositive power over 5,329,691 shares of Sarepta common stock and no sole dispositive power, indicating decisions to sell are made on a shared basis.

How are AQR Capital Management, LLC and AQR Capital Management Holdings, LLC related in this SRPT filing?

The exhibit explains that AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule 13G/A is filed on behalf of both entities.

When is the ownership information for AQR’s Sarepta (SRPT) stake stated as of?

The ownership information is stated as of June 30, 2026, with the Schedule 13G/A Amendment No. 1 later signed on August 13, 2026 by an authorized signatory.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 01:39 PM Accepted by SEC EDGAR 08/13/2026 - 01:39 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Sarepta Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

803607100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 803607100

1

Names of Reporting Persons

AQR Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,916,753.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,329,691.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,329,691.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.05 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 803607100

1

Names of Reporting Persons

AQR Capital Management Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,916,753.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,329,691.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,329,691.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.05 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sarepta Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 215 FIRST STREET, SUITE 415, CAMBRIDGE, MASSACHUSETTS 02142
Item 2.
(a)	Name of person filing: AQR Capital Management, LLC AQR Capital Management Holdings, LLC
(b)	Address or principal business office or, if none, residence: ONE GREENWICH PLAZA SUITE 130 Greenwich, Connecticut 06830
(c)	Citizenship: AQR Capital Management, LLC - UNITED STATES AQR Capital Management Holdings, LLC - UNITED STATES
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 803607100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,329,691 The reported amount includes Convertible Notes representing 1,004,002 shares of Common Stock, $0.0001 par value per share
(b)	Percent of class: 5.05 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: AQR Capital Management, LLC - 0 AQR Capital Management Holdings, LLC - 0
	(ii) Shared power to vote or to direct the vote: AQR Capital Management, LLC - 4,916,753 AQR Capital Management Holdings, LLC - 4,916,753
	(iii) Sole power to dispose or to direct the disposition of: AQR Capital Management, LLC - 0 AQR Capital Management Holdings, LLC - 0
	(iv) Shared power to dispose or to direct the disposition of: AQR Capital Management, LLC - 5,329,691 AQR Capital Management Holdings, LLC - 5,329,691
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Item 2(a) above.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AQR Capital Management, LLC

Signature:	Henry Parkin
Name/Title:	Authorized Signatory
Date:	08/13/2026

AQR Capital Management Holdings, LLC

Signature:	Henry Parkin
Name/Title:	Authorized Signatory
Date:	08/13/2026

Exhibit Information

AQR Capital Management Holdings, LLC and AQR Capital Management, LLC hereby agree that this Schedule 13G is filed on behalf of each of the parties. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.